ANE Corporación Acciona Energías Renovables, S.A.
Corporación Acciona Energías Renovables, S.A. engages in the promotion, construction, operation, maintenance, and development of renewable energy projects in Spain and internationally. The company operates onshore wind, photovoltaic solar, solar thermal, biomass, hydraulic, and energy storage renewable technology projects. It is also involved in renewable energy supply, green hydrogen, energy efficiency, electric mobility, and self-consumption decarbonization solutions. In addition, the company engages in fuel imports and exports; and sales and co-generation services, including engineering, consulting, and auditing of sites and projects, as well as drafting plans. The company was incorporated in 2008 and is headquartered in Madrid, Spain. Corporación Acciona Energías Renovables, S.A. operates as a subsidiary of Acciona, S.A.…
Industry Peers
Utilities - RenewableKey Statistics
About Corporación Acciona Energías Renovables (BME: ANE)
›
Corporación Acciona Energías Renovables (BME: ANE) is listed on the Bolsa de Madrid, where its shares trade in EUR. It belongs to the Utilities - Renewable industry, part of the Utilities sector, and reports about 2,933 employees.
The shares were at 19.35 EUR on 19 November 2026, down 6.7% over 52 weeks. Its 52-week range is 18.69 EUR to 24.86 EUR: the price is 22.2% below the high and 3.5% above the low.
At a market capitalisation of 6.28B EUR, it trades at 33.9 times trailing earnings and 28.8 times forward earnings. The median trailing P/E of its 14 largest Utilities - Renewable peers is 27.8, a premium of 22% for ANE. It pays a dividend yielding 0.15% (it pays out 5% of its earnings), against a median of 3.93% among the dividend payers in that peer group.
Corporación Acciona Energías Renovables reports return on equity of 11.2%, an operating margin of 14.4% and revenue down 34.4% year over year.
Its debt exceeds its cash by 4.92B EUR, a debt-to-equity ratio of 0.88. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 19 analysts cover the stock, with an average rating of Hold; their mean price target of 23.33 EUR is 20.5% above the current price. The next earnings report is expected on 25 February 2027.